To investigate the mechanism underlying differential growth capabilities of TILs, we performed an immunophenotypic comparison of these AML BMMNC by using biomarkers for naïve T cells, including CD62L, CD45RA, CCR7, CD95 [26]. This evidence concerns the gene SELL and acute myeloid leukemia.